• Jan K Hennigs, Gunhild Keller, Hans Jörg Baumann, Friedemann Honecker, Stefan Kluge, Carsten Bokemeyer, Tim H Brümmendorf, and Hans Klose.
• Centre for Pulmonary Hypertension, University Medical Centre Hamburg - Eppendorf, 20246 Hamburg, Germany.
• BMC Pulm Med. 2011 Jan 1; 11: 30.

BackgroundPulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib.Case PresentationHere, we discuss the relevance of previously published cases and add another well-characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the possibility of dasatinib itself causing PH after long-term therapy and turn specialist's attention to this possible severe side effect.At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding haemodynamics are missing.ConclusionWe therefore recommend systematic screening of dasatinib-treated patients for pulmonary hypertension and subsequent collection of haemodynamic data.

23 keywords...

hide…